Mehmet Fevzi Ozkaynak MD
Pediatric Solid Tumor Oncology
Professor of Pediatrics, New York Medical College
Join to view full profile
19 Bradhurst AvenueSuite 1400SHawthorne, NY 10532
Dr. Ozkaynak is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Children's Hospital Los AngelesResidency, Pediatrics, 1989 - 1991- Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1986 - 1989
Hacettepe University FOMClass of 1978
Certifications & Licensure
CA State Medical License 1990 - Present
NY State Medical License 1994 - 2028
CT State Medical License 1997 - 2027
ME State Medical License Active through 2006
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2010-2014
- Westchester Magazine: Top Doctors Castle Connolly, 2011
Clinical Trials
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 26
- Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Start of enrollment: 2004 Mar 15
- Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Publications & Presentations
PubMed
- 15 citationsCombinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.Yaya Chu, Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose
Molecular Therapy. Oncology. 2025-03-20 - Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803andin NB xenografts.Yaya Chu, Gaurav Nayyar, Meijuan Tian, Dean A Lee, Mehmet F Ozkaynak
Molecular Therapy. Oncology. 2024-06-20 - 33 citationsOutcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London
Journal of Clinical Oncology. 2022-12-10
Journal Articles
- The Safety and Efficacy of Clofarabine in Combination with High-Dose Cytarabine and Total Body Irradiation Myeloablative Conditioning and Allogeneic Stem Cell Transpla...Stacey Zahler, Mitchell S Cairo, Jennifer Krajewski, M Fevzi Ozkaynak, Alexandra C Cheerva, Theodore B Moore, Alfred P Gillio, Mark C Walters, Nature
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
